Company Analysis
Sign in

AnaptysBio, Inc. (ANAB)

Nasdaq: ANAB · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2006
Full chart Alerts Compare
Grade6.4
◀ Past 6.1● Present 6.3▶ Future 6.7
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of AnaptysBio, Inc.

Nine metrics read from its own filings, by tense
Headline grade
6.4/10
◀ Past6.130% of the headline
● Present6.340% of the headline
▶ Future6.730% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

6.1/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 33% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

AnaptysBio, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
4.8/10

What has it actually done, year after year?

+48.4% a year over 9 filed years; profitable in 0 of 9.

weight 45% of this tense · 48th percentile among 323 sector filers · read for its customers

From the record

AnaptysBio, Inc.'s 9 filed years say what it did: revenue went from $10 million in fiscal 2017 to $235 million in fiscal 2025, up 48.4% a year; it rose in 5 of 8 years; the deepest fall was 86% from fiscal 2020 to fiscal 2022; net income was positive in 0 of 9 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span48.4%top 25% of its family
  • the share of years revenue rosetop 48% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak86.3%bottom 36% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
5.8/10

How has it treated the people who own it?

SI estimate 5.8/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 295 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 295 members with one.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
family median, 295 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: AnaptysBio, Inc.'s shareholder treatment is put at 5.8 of 10 with a confidence of 20 of 100, because fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 295 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

● Present

What are they doing right now?

6.3/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

SI estimate
5.1/10

Is it financially healthy right now?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 480 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
Fewer than two of the four checks can be read, so the desk assumes the typical reading of its industry family, the median of 480 members with one.
What the record cannot read
Fewer than two of the four checks can be read.
How it was reasoned
family median, 480 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: AnaptysBio, Inc.'s financial health is put at 5.1 of 10 with a confidence of 20 of 100, because fewer than two of the four checks can be read, so the desk assumes the typical reading of its industry family, the median of 480 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Industry position

as filed
7.9/10

How strong is its position in its industry?

top 21% of 315 in its family; net margin -5.6%.

weight 33% of this tense · 79th percentile among 315 sector filers · read for its customers

From the record

AnaptysBio, Inc.'s standing among 315 graded names in its industry family: revenue of $235 million in fiscal 2025 ranks in the top 27% by size; a net margin of -5.6% ranks in the top 27%; revenue growth of 183.5% a year over the last 3 filed years ranks in the top 7% (its annual reports).

What it rests on

  • revenue against the family$235Mtop 27% of its family
  • net margin-5.6%top 27% of its family
  • three-year revenue growth183.5%top 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
6.2/10

What are the people in charge doing?

top 38% of 315 in its family for leadership; chief executive since 2022.

weight 22% of this tense · 62nd percentile among 315 sector filers · read for its shareholders

From the record

AnaptysBio, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Faga, Daniel (President, CEO, as filed), filing under that title since 2022-03-23, 4.6 years (bottom 45% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 6.1 years (top 40%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 18%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge3 in three years among 14 peopletop 18% of its family
  • the median years the people in charge have filed6.1 yearstop 40% of its family
  • the chief executive's years on the record4.6 yearsbottom 45% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

6.7/1030% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

SI estimate
6.3/10

How much room does it have to grow?

SI estimate 6.3/10, confidence 35 of 100 (one part).

weight 45% of this tense · 63rd percentile among 479 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, cash less debt against assets, which ranks in the top 37% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read
The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned
one part: cash less debt against assets, the one part on file, ranked among 479 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: AnaptysBio, Inc.'s room to expand is put at 6.3 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 37% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed
7.1/10

What could actually drive growth from here?

top 29% of 306 in its family for growth drivers.

weight 33% of this tense · 71st percentile among 306 sector filers · read for its customers

From the record

AnaptysBio, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 183.5% a year over the last three filed years against 48.4% over all 9, speeding up (top 3% of its family); the newest year grew 157.2% (top 13%); research spending grew 15.3% a year (top 31%); capital spending grew -37.6% a year (bottom 32%) (its annual reports). AnaptysBio, Inc. reported 2 lines of business in fiscal 2025: Royalty Management Company at $235 million, Biopharma Company at $0 thousand. Their growth is not matched year over year yet, and the largest line is 100% of revenue (its annual report).

What it rests on

  • three-year growth against the whole span+135.2 points a yeartop 3% of its family
  • the newest year's revenue growth157.2%top 13% of its family
  • three-year growth of research spending15.3%top 31% of its family
  • three-year growth of capital spending-37.6%bottom 32% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
6.8/10

Did its newest year beat what its own record pointed to?

top 32% of 233 in its family for expectations against reality.

weight 22% of this tense · 68th percentile among 233 sector filers · read for its shareholders

From the record

AnaptysBio, Inc.'s newest year against its own record: revenue of $235 million in fiscal 2025 came in 13.7% below the $272 million its prior three years' pace pointed to (bottom 37% of its family); net income of $13 million against a prior three-year average of $146 million (top 18%); a net margin of -5.6% against losses larger than its revenue before (top 15%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace-13.7%bottom 37% of its family
  • net income against the prior three years' average+91%top 18% of its family
  • net margin against its prior averageup more than 100 pointstop 15% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton ANAB · research, not advice